Venus Medtech (Hangzhou) Inc. (VMTHF)
VMTHF Stock Price Chart
Explore Venus Medtech (Hangzhou) Inc. interactive price chart. Choose custom timeframes to analyze VMTHF price movements and trends.
VMTHF Company Profile
Discover essential business fundamentals and corporate details for Venus Medtech (Hangzhou) Inc. (VMTHF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
30 Apr 2021
Employees
691.00
Website
https://www.venusmedtech.comCEO
Hou-Sen Lim MEng.
Description
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
VMTHF Financial Timeline
Browse a chronological timeline of Venus Medtech (Hangzhou) Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 26 Mar 2026
Earnings released on 28 Aug 2025
EPS came in at -$0.04 surpassing the estimated -$0.05 by +11.43%, while revenue for the quarter reached $26.11M , missing expectations by -35.03%.
Earnings released on 28 Mar 2025
Earnings released on 30 Aug 2024
EPS came in at -$0.47 falling short of the estimated -$0.06 by -736.06%, while revenue for the quarter reached $230.72M , beating expectations by +556.83%.
Earnings released on 28 Jun 2024
EPS came in at -$0.81 falling short of the estimated -$0.08 by -871.62%, while revenue for the quarter reached $235.76M , beating expectations by +544.40%.
Earnings released on 30 Jun 2023
EPS came in at -$0.80 falling short of the estimated -$0.09 by -765.76%, while revenue for the quarter reached $255.61M , beating expectations by +633.08%.
Earnings released on 31 Dec 2022
EPS came in at -$1.95 falling short of the estimated -$0.05 by -4.12K%, while revenue for the quarter reached $196.50M , beating expectations by +515.79%.
Earnings released on 31 Aug 2022
EPS came in at -$0.07 falling short of the estimated -$0.02 by -253.87%, while revenue for the quarter reached $31.33M , missing expectations by -9.43%.
Earnings released on 31 Dec 2021
EPS came in at -$0.43 falling short of the estimated -$0.03 by -1.49K%, while revenue for the quarter reached $207.93M , beating expectations by +623.10%.
Earnings released on 30 Jun 2021
EPS came in at -$0.43 falling short of the estimated -$0.02 by -2.02K%, while revenue for the quarter reached $207.93M , beating expectations by +499.57%.
Earnings released on 31 Dec 2020
EPS came in at -$0.22 falling short of the estimated -$0.00 by -7.17K%, while revenue for the quarter reached $138.02M , beating expectations by +269.18%.
VMTHF Stock Performance
Access detailed VMTHF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.